^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tyrosine kinase inhibitor

    Related drugs:
    Apply
    Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) (NCT06082167)
    Phase 2/3
    Exelixis
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    06/07/2024
    Primary completion :
    08/01/2028
    Completion :
    03/01/2029
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (CA209-982) (NCT03583086)
    Phase 1/2
    Vanderbilt-Ingram Cancer Center
    Completed
    Last update posted :
    10/08/2024
    Initiation :
    07/10/2018
    Primary completion :
    02/21/2024
    Completion :
    04/27/2024
    EGFR • PD-L1 • BRAF • ROS1
    |
    Opdivo (nivolumab) • Fumena (vorolanib)
    Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients (NCT06561620)
    Phase 4
    Fudan University
    Recruiting
    Last update posted :
    08/22/2024
    Initiation :
    05/01/2024
    Primary completion :
    05/01/2027
    Completion :
    05/01/2029
    EGFR
    |
    Semena (befotertinib)
    A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies (NCT03198650)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/27/2017
    Primary completion :
    10/27/2022
    Completion :
    12/13/2024
    CD20 • CD5 • FCER2
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (NCT01841723)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    04/30/2013
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Imbruvica (ibrutinib)
    Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia (ASC4KIDS) (NCT04925479)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    12/27/2021
    Primary completion :
    06/30/2026
    Completion :
    11/01/2031
    ABL1 • BCR
    |
    Scemblix (asciminib)
    A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (SHINE ) (NCT01776840)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2013
    Primary completion :
    06/01/2021
    Completion :
    06/01/2024
    CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 expression
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/11/2016
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (NCT05014464)
    Phase N/A
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    11/13/2021
    Primary completion :
    06/01/2026
    Completion :
    08/08/2027
    ALK
    |
    ALK positive
    |
    Xalkori (crizotinib) • pemetrexed
    Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04329325)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/30/2020
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    ABL1 • BCR
    |
    BCR-ABL1 fusion
    |
    dasatinib • Blincyto (blinatumomab) • dexamethasone • hydroxyurea
    A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2) (NCT05967689)
    Phase 2
    Taiho Oncology, Inc.
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    07/27/2023
    Primary completion :
    06/30/2025
    Completion :
    10/20/2025
    EGFR
    |
    EGFR mutation
    |
    zipalertinib (CLN-081)
    A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC) (NCT05456256)
    Phase 2
    Lantern Pharma Inc.
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    08/12/2022
    Primary completion :
    11/01/2024
    Completion :
    05/01/2025
    EGFR • ALK • NTRK
    |
    MET exon 14 mutation
    |
    carboplatin • pemetrexed • Pemfexy (pemetrexed) • Tavocept (dimesna)
    Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations (NCT05845671)
    Phase 1/2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    07/11/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    RET • ROS1
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    Rybrevant (amivantamab-vmjw)
    Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. (ASC4OPT) (NCT04948333)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    10/13/2021
    Primary completion :
    06/28/2024
    Completion :
    07/31/2026
    ABL1 • BCR
    |
    Scemblix (asciminib)
    REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (NCT05973773)
    Phase 3
    Taiho Oncology, Inc.
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    06/30/2023
    Primary completion :
    07/27/2026
    Completion :
    08/24/2026
    EGFR
    |
    EGFR mutation
    |
    carboplatin • zipalertinib (CLN-081)
    Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC (NCT05805631)
    Phase 2
    Taipei Veterans General Hospital, Taiwan
    Not yet recruiting
    Last update posted :
    05/01/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • pemetrexed
    The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP (NCT06390306)
    Phase N/A
    Peking University People's Hospital
    Not yet recruiting
    Last update posted :
    05/01/2024
    Initiation :
    05/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BCL2
    |
    Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • Nailike (olverembatinib)
    Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (RAMOSE) (NCT03909334)
    Phase 2
    Xiuning Le
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    07/25/2019
    Primary completion :
    05/01/2024
    Completion :
    06/01/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (CLN-081-001) (NCT04036682)
    Phase 1/2
    Cullinan Therapeutics Inc.
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    10/31/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR
    |
    EGFR mutation
    |
    zipalertinib (CLN-081)
    Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation (NCT04838041)
    Phase 2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    11/11/2021
    Primary completion :
    06/01/2028
    Completion :
    07/01/2029
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT05143840)
    Phase 2
    Augusta University
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    04/22/2022
    Primary completion :
    02/01/2025
    Completion :
    02/01/2027
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System (NCT05753384)
    Phase 3
    Poitiers University Hospital
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    12/01/2023
    Primary completion :
    12/01/2028
    Completion :
    12/01/2029
    ABL1 • BCR
    Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) (NCT05425940)
    Phase 3
    Exelixis
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    09/07/2022
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    MSI
    |
    MSI-H/dMMR • RAS mutation
    |
    Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)
    Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer (NCT04362072)
    Phase 4
    Pfizer
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    09/29/2020
    Primary completion :
    06/25/2024
    Completion :
    06/25/2024
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04501614)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    03/04/2024
    Initiation :
    02/24/2021
    Primary completion :
    12/19/2024
    Completion :
    01/04/2027
    ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4
    |
    BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    cytarabine • Iclusig (ponatinib) • cyclophosphamide
    A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies (NCT03321630)
    Phase 2
    NYU Langone Health
    Completed
    Last update posted :
    02/29/2024
    Initiation :
    10/24/2017
    Primary completion :
    03/10/2023
    Completion :
    01/16/2024
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled (NCT06282991)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    07/22/2020
    Primary completion :
    01/18/2021
    Completion :
    01/18/2021
    ALK
    |
    Lorbrena (lorlatinib)
    A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) (NCT04540705)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/11/2020
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    PD-L1
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib) • bempegaldesleukin (NKTR-214)
    ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor (NCT04216563)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/22/2024
    Initiation :
    07/29/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    ABL1 • BCR
    |
    Scemblix (asciminib)
    A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166)
    Phase 1
    Exelixis
    Active, not recruiting
    Last update posted :
    02/19/2024
    Initiation :
    03/20/2019
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    HER-2 • KRAS • BRAF • NRAS • MSI
    |
    BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)
    Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. (KIWIS) (NCT03996096)
    Phase N/A
    University Hospital, Caen
    Completed
    Last update posted :
    02/14/2024
    Initiation :
    04/23/2019
    Primary completion :
    03/16/2023
    Completion :
    03/16/2023
    VEGFA • IFNG • IL6 • TNFA • IL2 • IL10 • TGFB1 • TNFRSF11B
    Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (NCT03238196)
    Phase 1
    Vanderbilt-Ingram Cancer Center
    Active, not recruiting
    Last update posted :
    02/01/2024
    Initiation :
    08/18/2017
    Primary completion :
    04/30/2021
    Completion :
    09/25/2024
    HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23
    |
    HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification
    |
    Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant
    Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2) (NCT04401059)
    Phase 4
    Tian Xie
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    11/09/2020
    Primary completion :
    09/30/2025
    Completion :
    03/30/2026
    EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1
    |
    EGFR mutation • EGFR L858R • EGFR positive
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)
    Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) (NCT04621188)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Recruiting
    Last update posted :
    12/19/2023
    Initiation :
    03/19/2021
    Primary completion :
    03/01/2025
    Completion :
    01/01/2026
    ROS1
    |
    ROS1 rearrangement
    |
    Lorbrena (lorlatinib)
    Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN) (NCT04626024)
    Phase 2
    Baylor College of Medicine
    Recruiting
    Last update posted :
    12/13/2023
    Initiation :
    12/22/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2025
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Bosulif (bosutinib)
    Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease (ECOG-ACRIN EA9171) (NCT03516279)
    Phase 2
    ECOG-ACRIN Cancer Research Group
    Recruiting
    Last update posted :
    11/28/2023
    Initiation :
    06/26/2019
    Primary completion :
    08/31/2028
    Completion :
    08/31/2031
    ABL1 • BCR • CD4
    |
    Keytruda (pembrolizumab) • dasatinib • imatinib • Tasigna (nilotinib)
    Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (NCT03654768)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    11/13/2023
    Initiation :
    10/24/2018
    Primary completion :
    07/01/2024
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    dasatinib • imatinib • Jakafi (ruxolitinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
    Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (NCT02584478)
    Phase 3
    Advenchen Laboratories, LLC
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    12/01/2015
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    BRCA
    |
    BRCA mutation
    |
    carboplatin • paclitaxel • Focus V (anlotinib) • pegylated liposomal doxorubicin • topotecan
    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies (NCT02629692)
    Phase 1/2
    Sun Pharma Advanced Research Company Limited
    Active, not recruiting
    Last update posted :
    10/27/2023
    Initiation :
    04/25/2017
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    ABL1 • BCR
    |
    vodobatinib (SCO - 088)
    Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors (NCT05495828)
    Phase N/A
    Peking University People's Hospital
    Recruiting
    Last update posted :
    10/26/2023
    Initiation :
    11/10/2023
    Primary completion :
    12/10/2024
    Completion :
    03/10/2025
    CCND1
    |
    CCND1 expression
    |
    Inokai (orelabrutinib)